279
from conventional delivery to a versatile delivery system due to
presence of flexible cross-linked polymers, and fulfils the aforementioned required characteristics. The required particle size, viscosity,
and release rate can be attained by controlling the polymer-tocross-linker ratio. Nanosponge-based delivery systems also address
the solubility dilemma that is associated with newly developed
drug entities, and protect the active moieties from degradation.
Various dosage forms of the same drug can be formulated as
desired, and the side effects associated with conventional formulations can be overcome by advanced approaches like stimuli- sensitive
nanosponges and tumor targeting. To sum, cyclodextrin-based
nanosponges with multitude number of beneficial attributes can
contribute as a promising tool for effective and efficient drug delivery, and can be endorsed as an advanced carrier in the field of drug
delivery and nanotherapeutics.
References
1. Trotta F, Zanetti M, Cavalli R (2012)
Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem 8:2091–2099
2. Cavalli R, Trotta F, Tumiatti W (2006)
Cyclodextrin-based nanosponges for drug
delivery. J Incl Phenom Macrocycl Chem
56(1–2):209–213
3. Jaya Raju L, Rui Werner Maçedo K (2014) A
vision for cyclodextrin nanoparticles in drug
delivery systems and pharmaceutical applications. Nanomedicine 9(6):877–894
4. Trotta F, Cavalli R (2009) Characterization
and applications of new hyper-crosslinked cyclodextrins. Composite Interfaces
16(1):39–48
5. Trotta F (2011) Cyclodextrins in pharmaceutics, cosmetics, and biomedicine: current and
future industrial applications. In: Cyclodextrin
Nanosponges and their applications. John
Wiley & Sons, Inc., Hoboken, pp 323–342
6. Trotta F (2016) Cyclodextrin in membranes.
In: Encyclopedia of membranes. Springer,
Berlin, Heidelberg, pp 505–507
7. Allahyari S, Trotta F, Valizadeh H et al (2019)
Cyclodextrin based nanosponges as promising carriers for active agents. Expert Opin
Drug Deliv 16:467–479
8. Sai VC, Priti PP, Kisan RJ et al (2014)
Cyclodextrin-based nanosponges: a propitious platform for enhancing drug delivery.
Expert Opin Drug Deliv 11(1):111–120
9. Osmani AM, Rohit RB, Umme H et al (2015)
Cyclodextrin based nanosponges: impending
carters in drug delivery and nanotherapeutics.
Curr Drug Ther 10(1):3–19
10. Trotta F, Shende P, Biasizzo M (2012)
Method for preparing dextrin nanosponges.
Patent WO 147069
11. Trotta F, Cavalli R, Tumiatti W et al (2006)
Cyclodextrin-based nanosponges as a vehicle
for antitumoral drugs WO 06/002814,
12. Ferruti P, Ranucci E, Trotta F et al (2013)
Hyperbranched polymers based on cyclodextrins and poly (amidoamines) for the controlled release of insoluble drugs. US Patent
No 8,372,933
13. Ferruti P (2008) Nanospugne a base di
ciclodestrine come supporto per catalizzatori biologici e nella veicolazione e rilascio
di enzimi, proteine, vaccini ed anticorpi. IT
MI2008A1056
14. Trotta F, Cavalli R, Tumiatti W et al (2007)
Ultrasound-assisted synthesis of cyclodextrinbased nanosponges. EP1 786 841 B1
15. Shende P, Kulkarni YA, Gaud RS et al (2015)
Acute and repeated dose toxicity studies of
different b-cyclodextrin-based nanosponge
formulations. Pharmacokinet Pharmacodyn
Drug Transport Metab 104:1856–1863
16. Caldera F, Tannous M, Cavalli R et al (2017)
Evolution of cyclodextrin nanosponges. Int J
Pharm 531(2):470–479
17. Swaminathan S, Cavalli R, Trotta F (2016)
Cyclodextrin-based nanosponges: a versatile
platform for cancer nanotherapeutics development. Wiley Interdiscip Rev Nanomed
Nanobiotechnol 8(4):579–601
18. Trotta F, Dianzani C, Caldera F et al (2014)
The application of nanosponges to cancer drug delivery. Expert Opin Drug Deliv
11(6):931–941
Drug-Encapsulated Cyclodextrin Nanosponges
from conventional delivery to a versatile delivery system due to
presence of flexible cross-linked polymers, and fulfils the aforementioned required characteristics. The required particle size, viscosity,
and release rate can be attained by controlling the polymer-tocross-linker ratio. Nanosponge-based delivery systems also address
the solubility dilemma that is associated with newly developed
drug entities, and protect the active moieties from degradation.
Various dosage forms of the same drug can be formulated as
desired, and the side effects associated with conventional formulations can be overcome by advanced approaches like stimuli- sensitive
nanosponges and tumor targeting. To sum, cyclodextrin-based
nanosponges with multitude number of beneficial attributes can
contribute as a promising tool for effective and efficient drug delivery, and can be endorsed as an advanced carrier in the field of drug
delivery and nanotherapeutics.
References
1. Trotta F, Zanetti M, Cavalli R (2012)
Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem 8:2091–2099
2. Cavalli R, Trotta F, Tumiatti W (2006)
Cyclodextrin-based nanosponges for drug
delivery. J Incl Phenom Macrocycl Chem
56(1–2):209–213
3. Jaya Raju L, Rui Werner Maçedo K (2014) A
vision for cyclodextrin nanoparticles in drug
delivery systems and pharmaceutical applications. Nanomedicine 9(6):877–894
4. Trotta F, Cavalli R (2009) Characterization
and applications of new hyper-crosslinked cyclodextrins. Composite Interfaces
16(1):39–48
5. Trotta F (2011) Cyclodextrins in pharmaceutics, cosmetics, and biomedicine: current and
future industrial applications. In: Cyclodextrin
Nanosponges and their applications. John
Wiley & Sons, Inc., Hoboken, pp 323–342
6. Trotta F (2016) Cyclodextrin in membranes.
In: Encyclopedia of membranes. Springer,
Berlin, Heidelberg, pp 505–507
7. Allahyari S, Trotta F, Valizadeh H et al (2019)
Cyclodextrin based nanosponges as promising carriers for active agents. Expert Opin
Drug Deliv 16:467–479
8. Sai VC, Priti PP, Kisan RJ et al (2014)
Cyclodextrin-based nanosponges: a propitious platform for enhancing drug delivery.
Expert Opin Drug Deliv 11(1):111–120
9. Osmani AM, Rohit RB, Umme H et al (2015)
Cyclodextrin based nanosponges: impending
carters in drug delivery and nanotherapeutics.
Curr Drug Ther 10(1):3–19
10. Trotta F, Shende P, Biasizzo M (2012)
Method for preparing dextrin nanosponges.
Patent WO 147069
11. Trotta F, Cavalli R, Tumiatti W et al (2006)
Cyclodextrin-based nanosponges as a vehicle
for antitumoral drugs WO 06/002814,
12. Ferruti P, Ranucci E, Trotta F et al (2013)
Hyperbranched polymers based on cyclodextrins and poly (amidoamines) for the controlled release of insoluble drugs. US Patent
No 8,372,933
13. Ferruti P (2008) Nanospugne a base di
ciclodestrine come supporto per catalizzatori biologici e nella veicolazione e rilascio
di enzimi, proteine, vaccini ed anticorpi. IT
MI2008A1056
14. Trotta F, Cavalli R, Tumiatti W et al (2007)
Ultrasound-assisted synthesis of cyclodextrinbased nanosponges. EP1 786 841 B1
15. Shende P, Kulkarni YA, Gaud RS et al (2015)
Acute and repeated dose toxicity studies of
different b-cyclodextrin-based nanosponge
formulations. Pharmacokinet Pharmacodyn
Drug Transport Metab 104:1856–1863
16. Caldera F, Tannous M, Cavalli R et al (2017)
Evolution of cyclodextrin nanosponges. Int J
Pharm 531(2):470–479
17. Swaminathan S, Cavalli R, Trotta F (2016)
Cyclodextrin-based nanosponges: a versatile
platform for cancer nanotherapeutics development. Wiley Interdiscip Rev Nanomed
Nanobiotechnol 8(4):579–601
18. Trotta F, Dianzani C, Caldera F et al (2014)
The application of nanosponges to cancer drug delivery. Expert Opin Drug Deliv
11(6):931–941
Drug-Encapsulated Cyclodextrin Nanosponges